Markets
Mounjaro Photo Illustrations
(Getty Images)

Eli Lilly rises after earnings, sales blow past Wall Street’s expectations

The company sold $6.5 billion worth of Mounjaro in this most recent quarter, $1 billion more than the Street was expecting.

J. Edward Moreno

Eli Lilly rose after it reported earnings and revenue that beat Wall Street expectations, driven by better-than-expected sales of its blockbuster diabetes shot Mounjaro.

The company reported adjusted earnings per share of $7.02, compared to the $5.89 analysts polled by FactSet were expecting. It also reported $17.6 billion in sales, versus the $16 billion the Street was penciling in. Both its top- and bottom-line results were better than every analyst polled by Bloomberg had projected.

The drugmaker’s sales growth is largely driven by its diabetes and weight-loss shots, Mounjaro and Zepbound. The company sold $6.5 billion worth of Mounjaro in the latest quarter, $1 billion more than the Street was expecting.

Lilly raised its full-year adjusted profit outlook to between $23 and $23.70 per share, up from its previous guidance of $21.75 to $23 a share. It now expects annual revenue to hit between $63 billion and $63.5 billion, up from its previous guidance of $60 billion to $62 billion. 

Tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound, is now the most-sold medicine in the world, surpassing Merck’scancer therapy, Keytruda, this year.

But despite having some of the bestselling pharmaceuticals on the market, the company is underperforming the broader market for the year, as uncertainty over tariffs and drug pricing roils the industry.

The company has doubled down on direct-to-consumer sales for Zepbound, its popular weight-loss drug that is often not covered by insurance. It offers cheaper cash-pay versions for patients bypassing insurance, and Wednesday announced it would partner with Walmart to distribute the drug.

Brian Mulberry, a portfolio manager at Zacks Investment Management, said that while Lilly's fundamentals are solid, expectations remain high. In its last quarterly report, its earnings beat was overshadowed by trial results that disappointed Wall Street.

"For an investor, this appears like a growth-at-a-premium story: the rewards could be substantial if execution remains strong and the pipeline delivers, but the risks are elevated given high expectations and external headwinds," Mulberry said.

The search for the next blockbuster weight-loss drug is well underway, with Lilly, Novo and several others working on new injectables and the next frontier: pills, which are cheaper to manufacture and could be more inviting for those scared of needles.

Meanwhile, Novo andPfizer are in a bidding war for Metsera, a small biotech working on next-gen GLP-1s.

More Markets

See all Markets
markets

Synopsys rises on WSJ report of Elliott’s new multibillion-dollar stake

Software company Synopsys is up 3% in premarket trading on Monday after the Wall Street Journal reported that Elliott Investment Management, a well-known activist fund, has taken a multibillion-dollar stake in the company.

Elliott’s managing partner Jesse Cohn told the WSJ that “Synopsys is essential to the global chip industry,” and that it is “uniquely positioned to benefit” as the AI industry continues to require more capital, more complex chips, and therefore, more software to design them.

The investment firm's investment is predicated on a “clear opportunity for Synopsys’ financial performance to more fully reflect the value it delivers.” While memory stocks like Micron have been on a tear recently, Synopsys has dropped 8% over the past year, lagging behind its biggest rival Cadence Design Systems, which is up 6% in the same period.

Citing people familiar with the investment in Synopsys, the Journal reports that Elliott sees room for the company to boost sales and improve its margins to be more in line with that of Cadence. In its fiscal year 2025, Cadence notched an adjusted operating margin of nearly 45%, Synopsys only eked out 37%.

Elliott’s managing partner Jesse Cohn told the WSJ that “Synopsys is essential to the global chip industry,” and that it is “uniquely positioned to benefit” as the AI industry continues to require more capital, more complex chips, and therefore, more software to design them.

The investment firm's investment is predicated on a “clear opportunity for Synopsys’ financial performance to more fully reflect the value it delivers.” While memory stocks like Micron have been on a tear recently, Synopsys has dropped 8% over the past year, lagging behind its biggest rival Cadence Design Systems, which is up 6% in the same period.

Citing people familiar with the investment in Synopsys, the Journal reports that Elliott sees room for the company to boost sales and improve its margins to be more in line with that of Cadence. In its fiscal year 2025, Cadence notched an adjusted operating margin of nearly 45%, Synopsys only eked out 37%.

markets

Exxon and Chevron surge as oil rises; gold keeps getting clobbered

Exxon and Chevron jumped again on Friday, the two largest positive contributors to the S&P 500 as of midday, even as the broader market remained mired in the red.

The two giant US energy companies are also on track to notch another in a series of new all-time highs as well Friday, and for obvious reasons.

Energy continues to be the bright spot for the S&P 500 since the start of the Iran war. (It is the only gainer of the 11 separate sectors that compose the blue-chip index, rising more than 7% in March.)

But energy’s gain has come with pain elsewhere. Since rising gas prices work mechanically as a tax on other forms of consumer spending, staples stocks have been hit hard, with the sector down more than 6% this month alone. Meanwhile, the inflationary pressure pushing the Fed away from further rate cuts continues to hit precious metals and miners. SPDR Gold Shares ETF and iShares Silver Trust futures both fell further on Friday; they’re down roughly 10% and 15% for the week, respectively, and producers like Newmont and Freeport-McMoRan also continue to drop.

markets

Investors have been drawn to software stocks since the Iran war started — Figma has been an exception

Since the Iran war started, risky assets have been in the crosshairs. Stocks have sold off as oil prices spiked, the odds of rate cuts later this year have been slashed, and even the usual safe havens like gold and silver have been unreliable ports in the growing storm.

One port of refuge, however, has been in software stocks. As noted by my colleague Matt Phillips recently, a number of high-profile software names — the same ones that some pundits doomed to obsolescence because of AI just a few short weeks ago — have held up well. Design company Figma, however, has not been one of those names.

Figmas stock has dropped 19% since the close of trading on February 27, while the iShares Expanded Tech Software ETF has gained 2%.

Though still notching very respectable top-line growth, with sales up 40% last year, Figma is far from the cash cow stage of its life — perhaps why its been hit harder than peers such as Adobe, Workday, or Salesforce. Indeed, on a GAAP basis, Wall Street still expects the company to lose $477 million this year, as heavy stock-based compensation weighs on its profitability.

Figmas pain was then compounded when Google announced a major update to Stitch on Wednesday — a product described as an AI-native software design canvas that allows anyone to create, iterate and collaborate on high-fidelity UI from natural language.

Debate is still raging on Reddit and other social media platforms as to whether Stitch, or other vibe-coding platforms and tools, will meaningfully eat into Figmas core business. One user said that it offers very little to experienced designers. It removes the tools Figma offers and delegates everything to AI. Figma at least has all the capabilities plus AI for people who want to use AI. Another — complaining about the newly prohibitive cost of credits in Figmas own AI-powered tool, Figma Make — was more bearish on Figmas usefulness, saying that the number of credits the designer would need to use would cost $16,000 under Figmas new pricing model.

For now, investors arent giving Figma the benefit of the doubt, with the stock down 12% in the last two days alone.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.